Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

C4042

Sigma-Aldrich

Captopril

≥98% (HPLC), powder, angiotensin converting enzyme inhibitor

Sinónimos:

N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C9H15NO3S
Número de CAS:
62571-86-2
Peso molecular:
217.29
Beilstein/REAXYS Number:
477887
EC Number:
263-607-1
MDL number:
MFCD00168073
UNSPSC Code:
12352200
PubChem Substance ID:
57654003
NACRES:
NA.77

product name

Captopril, ≥98% (HPLC), powder

biological source

synthetic

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to off-white

mp

104-108 °C (lit.)

solubility

water: 100 mg/mL, clear to very slightly hazy, colorless to faintly yellow

originator

Bristol-Myers Squibb

storage temp.

room temp

SMILES string

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

InChI key

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Gene Information

human ... ACE(1636) , AGTR1(185) , AGTR2(186) , ECE1(1889)
rat ... Ace(24310)

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

Captopril has been used:
  • to examine the influence of timing of captopril treatment on efficacy in transverse aortic constriction (TAC) mice
  • as an angiotensin-converting enzyme inhibitor and orally administered to unrestrained Wistar Kyoto rats in an approach to study its effects of angiogenesis inhibition and interdependency with other drugs
  • used as a positive control in spectrophotometric assay to study the angiotensin-converting enzyme inhibitory activity

Biochem/physiol Actions

Captopril is known to decrease the cardiovascular complications arising due to myocardial infarction. It is an effective drug in treating diabetic nephropathy and renal disease. Captopril acts by reducing cardiac related inflammation, fibrosis and calcification.
Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Neuropeptidases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Muta. 2 - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Tami A Martino et al.
Journal of the American College of Cardiology, 57(20), 2020-2028 (2011-05-14)
Our objective was to test the hypothesis that there is a significant diurnal variation for the therapeutic benefit of angiotensin-converting enzyme (ACE) inhibitors on pressure-overload cardiovascular hypertrophy. Physiological and molecular processes exhibit diurnal rhythms that may affect efficacy of disease
The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy
Martino TA, et al.
Journal of the American College of Cardiology, 57(20), 2020-2028 (2011)
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
Pfeffer MA, et al.
The New England Journal of Medicine, 349(20), 1893-1906 (2003)
Identification of antihypertensive peptides derived from low molecular weight casein hydrolysates generated during fermentation by Bifidobacterium longum KACC 91563
Ha GE, et al.
Korean journal for food science of animal resources, 35(6), 738-738 (2015)
Henryk Zieliński et al.
Foods (Basel, Switzerland), 9(7) (2020-07-03)
The angiotensin converting enzyme (ACE) inhibitory activity and phenolics profile of fermented flours and of baked and digested buckwheat biscuits was studied. The fermentation of buckwheat flour by select lactic acid bacteria (LAB) caused a decrease in ACE inhibitory activity
Ver todos los artículos relacionados

Artículos

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico